Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AXGN

AXGN - AxoGen Inc Stock Price, Fair Value and News

$34.10-0.49 (-1.42%)
Market Closed

28/100

AXGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

28/100

AXGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$26.26

Target 3M

$29.81

Target 6M

$27.91

AXGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXGN Price Action

Last 7 days

3.3%

Last 30 days

1.9%

Last 90 days

50.3%

Trailing 12 Months

85.2%

AXGN RSI Chart

AXGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXGN Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-750.01

Price/Sales (Trailing)

7.33

EV/EBITDA

-464.84

Price/Free Cashflow

470.75

AXGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$26.26

Target 3M

$29.81

Target 6M

$27.91

AXGN Fundamentals

AXGN Revenue

Revenue (TTM)

214.7M

Rev. Growth (Yr)

23.51%

Rev. Growth (Qtr)

6.04%

AXGN Earnings

Earnings (TTM)

-2.1M

Earnings Growth (Yr)

138.11%

Earnings Growth (Qtr)

22.28%

AXGN Profitability

EBT Margin

-7.06%

Return on Equity

-1.74%

Return on Assets

-0.97%

Free Cashflow Yield

0.21%

AXGN Investor Care

Shares Dilution (1Y)

4.80%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025194.5M203.3M214.7M0
2024163.7M173.5M180.9M187.3M
2023144.2M147.9M152.3M159.0M
2022127.3M128.2M134.0M138.6M
2021119.1M130.5M128.3M127.4M
2020107.7M103.1M108.0M112.3M
201990.0M96.1M102.0M106.7M
201865.4M70.9M77.5M83.9M
201745.2M50.0M54.9M60.4M
201630.5M34.5M37.5M41.1M
201518.6M20.8M24.3M27.3M
201411.9M13.3M15.0M16.8M
20138.2M9.0M10.0M10.9M
20125.4M6.2M7.0M7.7M
20113.5M3.9M4.4M4.8M
20100003.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About AxoGen Inc

AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
 CEO
 WEBSITEaxogeninc.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES394

AxoGen Inc Frequently Asked Questions

AXGN is the stock ticker symbol of AxoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of AxoGen Inc is 1.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AXGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether AXGN is over valued or under valued. Whether AxoGen Inc is cheap or expensive depends on the assumptions which impact AxoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXGN.

As of Wed Jan 28 2026, AXGN's PE ratio (Price to Earnings) is -750.01 and Price to Sales (PS) ratio is 7.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXGN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, AxoGen Inc has provided 0.213 (multiply by 100 for percentage) rate of return.